Trial of Abiraterone Acetate Plus LHRH-therapy Versus Abiraterone Acetate Sparing LHRH-therapy in Patients With Progressive Chemotherapy-naïve Castration-resistant Prostate Cancer (SPARE)

NCT02077634 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

68

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: abiraterone acetate + prednisone + LHRH-therapy
DRUG: abiraterone acetate + prednisone

Sponsor

Universität des Saarlandes